The role of pharmacogenetics in the treatment of depression and anxiety disorders

2009 ◽  
Vol 24 (6) ◽  
pp. 277-288 ◽  
Author(s):  
Alexandra Schosser ◽  
Siegfried Kasper
Author(s):  
Daniela Felice ◽  
Anand Gururajan ◽  
Olivia F O’Leary ◽  
John F Cryan

Depression and anxiety disorders cause the greatest global disability in terms of impact on the individual, family, and society at large. The etiology of these disorders is multifactorial and includes complex interactions between genetic and environmental risk factors. This chapter reviews preclinical studies assessing the importance of gene–environment (G×E) interaction. Specifically, we focus on G×E studies assessing the roles of the hypothalamic–pituitary–adrenal (HPA) axis, serotonergic system, GABAergic system, and brain-derived neurotrophic factor (BDNF) system. Finally, novel candidate target genes for the treatment of depression and anxiety disorders are considered.


2020 ◽  
Vol 18 ◽  
Author(s):  
Shvetank Bhatt ◽  
Thangaraj Devadoss ◽  
SN Manjula ◽  
Jayaraman Rajangam

Background: Depression or Major depressive disorder (MDD) is prolonged condition of sadness. MDD is the most common mental disorder that affects more than 264 million people worldwide. According to monoamine hypothesis, serotonin (5-hydroxy tryptamine, 5-HT), dopamine (DA) and norepinephrine (NE) are the major neurotransmitters (NTs) involved in depression. Method: The methodology adopted for writing this review article is essentially based on the secondary literature search through systematic literature review. This review mainly focussed on the role of 5-HT3 receptor antagonists (5-HT3RA) in depression and comorbid disorder like anxiety. Results: Out of three major NTs mentioned above, serotonin has predominant role in the pathophysiology of depression. The serotonin type-3 receptors (5-HT3R) are well renowned to be expressed in the central nervous system (CNS) in regions which have significance in the vomiting reflex, perception of pain, the reward system, cognition, depression and anxiety control. The 5-HT3R is only receptor of serotonergic family that belongs to ligand gated ion channel. The 5-HT3RA inhibit the binding of serotonin to post synaptic 5-HT3R and increase its availability to other receptors like 5-HT1A, 1B and 1D as well as 5-HT2 receptors and produces anti-depressant-like effect. The 5-HT3RA also have important role in mood and stress disorders. Some of the studies have shown the effectiveness of these agents in stress disorder. Conclusion: The present article focused on the role of 5-HT3R and their antagonists in the treatment of depression and anxiety. Further studies are warranted to prove their efficacy with respect to other standard anti-depressants.


2018 ◽  
Vol 23 (9) ◽  
pp. 1136-1147 ◽  
Author(s):  
Michael J Scott

Improving Access to Psychological Therapies is a UK government-funded initiative to widen access to the psychological treatment of depression and anxiety disorders. The author has had the opportunity to independently assess 90 Improving Access to Psychological Therapies clients, using a standardised semi-structured interview, the Structured Clinical Diagnostic Interview for DSM Disorders (SCID) and to listen to their account of interaction with the service. The results suggest that only the tip of the iceberg fully recovers from their disorder (9.2%) whether or not they were treated before or after a personal injury claim. There is a pressing need to re-examine the modus operandi of the service.


Cureus ◽  
2020 ◽  
Author(s):  
Federico Oliveri ◽  
Harshit K Goud ◽  
Lubna Mohammed ◽  
Zainab Mehkari ◽  
Moiz Javed ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document